113 related articles for article (PubMed ID: 24770830)
21. Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy.
Ferrari SM; Ragusa F; Paparo SR; Nasini F; Nardi M; Franceschini SS; Fallahi P; Antonelli A
Autoimmun Rev; 2019 Jul; 18(7):673-678. PubMed ID: 31059842
[TBL] [Abstract][Full Text] [Related]
22. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
Antonelli A; Rotondi M; Fallahi P; Grosso M; Boni G; Ferrari SM; Romagnani P; Serio M; Mariani G; Ferrannini E
J Clin Endocrinol Metab; 2007 Apr; 92(4):1485-90. PubMed ID: 17244787
[TBL] [Abstract][Full Text] [Related]
23. Chemokines in thyroid autoimmunity.
Ferrari SM; Paparo SR; Ragusa F; Elia G; Mazzi V; Patrizio A; Ghionzoli M; Varricchi G; Centanni M; Ulisse S; Antonelli A; Fallahi P
Best Pract Res Clin Endocrinol Metab; 2023 Mar; 37(2):101773. PubMed ID: 36907786
[TBL] [Abstract][Full Text] [Related]
24. Novel Therapies for Thyroid Autoimmune Diseases.
Fallahi P; Ferrari SM; Elia G; Nasini F; Colaci M; Giuggioli D; Vita R; Benvenga S; Ferri C; Antonelli A
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):853-61. PubMed ID: 26900630
[TBL] [Abstract][Full Text] [Related]
25. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
De Bellis A; Di Martino S; Fiordelisi F; Muccitelli VI; Sinisi AA; Abbate GF; Gargano D; Bellastella A; Bizzarro A
J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
[TBL] [Abstract][Full Text] [Related]
26. [CXCR3 and CXCL10 in autoimmune thyroiditis].
Ruffilli I; Ferrari SM; Colaci M; Ferri C; Politti U; Antonelli A; Fallahi P
Clin Ter; 2014; 165(3):e237-42. PubMed ID: 24999582
[TBL] [Abstract][Full Text] [Related]
27. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma.
De Bellis A; Bizzarro A; Gattoni A; Romano C; Di Martino S; Sinisi AA; Abbadessa S; Bellastella A
J Clin Endocrinol Metab; 1995 Jul; 80(7):2118-21. PubMed ID: 7541801
[TBL] [Abstract][Full Text] [Related]
28. Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy.
Le Moli R; Muscia V; Tumminia A; Frittitta L; Buscema M; Palermo F; Sciacca L; Squatrito S; Vigneri R
Nutr Metab Cardiovasc Dis; 2015 May; 25(5):452-7. PubMed ID: 25746910
[TBL] [Abstract][Full Text] [Related]
29. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids.
Myśliwiec J; Kretowski A; Topolska J; Siewko K; Jakubczyk D; Szelachowska M; Mikita A; Kinalska I
Horm Metab Res; 2001 Dec; 33(12):739-43. PubMed ID: 11753760
[TBL] [Abstract][Full Text] [Related]
30. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes.
Crescioli C; Cosmi L; Borgogni E; Santarlasci V; Gelmini S; Sottili M; Sarchielli E; Mazzinghi B; Francalanci M; Pezzatini A; Perigli G; Vannelli GB; Annunziato F; Serio M
J Endocrinol; 2007 Oct; 195(1):145-55. PubMed ID: 17911406
[TBL] [Abstract][Full Text] [Related]
31. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
[TBL] [Abstract][Full Text] [Related]
32. Th1/Th2 cytokines in patients with Graves' disease with or without ophthalmopathy.
Esfahanian F; Naimi E; Doroodgar F; Jadali Z
Iran J Allergy Asthma Immunol; 2013 May; 12(2):168-75. PubMed ID: 23754356
[TBL] [Abstract][Full Text] [Related]
33. Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves' disease.
Leite AC; Pedro AB; Romaldini JH
Horm Metab Res; 2011 Mar; 43(3):194-9. PubMed ID: 21283953
[TBL] [Abstract][Full Text] [Related]
34. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy.
De Bellis A; Sansone D; Coronella C; Conte M; Iorio S; Perrino S; Battaglia M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
Clin Endocrinol (Oxf); 2005 Jan; 62(1):24-9. PubMed ID: 15638866
[TBL] [Abstract][Full Text] [Related]
35. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy.
Prabhakar BS; Bahn RS; Smith TJ
Endocr Rev; 2003 Dec; 24(6):802-35. PubMed ID: 14671007
[TBL] [Abstract][Full Text] [Related]
36. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes.
García-López MA; Sancho D; Sánchez-Madrid F; Marazuela M
J Clin Endocrinol Metab; 2001 Oct; 86(10):5008-16. PubMed ID: 11600578
[TBL] [Abstract][Full Text] [Related]
37. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.
Molnár I; Bokk A
Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110
[TBL] [Abstract][Full Text] [Related]
38. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous measurement of serum chemokines in autoimmune thyroid diseases: possible role of IP-10 in the inflammatory response.
Hiratsuka I; Itoh M; Yamada H; Yamamoto K; Tomatsu E; Makino M; Hashimoto S; Suzuki A
Endocr J; 2015; 62(12):1059-66. PubMed ID: 26400025
[TBL] [Abstract][Full Text] [Related]
40. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
Molnár I
Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
